Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The use of cannabinoids in multiple sclerosis.

Lara Teare¹, John Zajicek

¹Neurology Research Group, Peninsula Medical School, Plymouth PL6 8BX, UK.

Expert Opinion on Investigational Drugs

|July 19, 2005

Summary

Cannabinoids show potential for modulating multiple sclerosis models and may offer neuroprotection. Further research is needed to clarify their role in symptom relief and disease modification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Foslevodopa-foscarbidopa infusion.

Practical neurology·2025

Same author

Myoclonus-dystonia due to novel mutation in the guanine nucleotide-binding protein (GNB1) gene.

Parkinsonism & related disorders·2025

Same author

Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.

JAMA neurology·2022

Same author

Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.

BMJ open·2019

Same author

Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis.

The Lancet. Neurology·2019

Same author

A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.

Health technology assessment (Winchester, England)·2019

Area of Science:

Neuroscience
Pharmacology
Immunology

Background:

Cannabinoids, including Delta9-tetrahydrocannabinol and cannabidiol, are being investigated for their effects on multiple sclerosis (MS).
Endocannabinoids and synthetic cannabinoids also represent potential therapeutic agents.
Previous clinical studies on cannabinoids for MS symptoms yielded inconsistent results, possibly due to methodological limitations.

Purpose of the Study:

To explore the role of cannabinoids in experimental models of multiple sclerosis.
To evaluate the potential of cannabinoids for symptom relief in MS patients.
To investigate the neuroprotective properties of cannabinoids in the context of MS.

Main Methods:

Review of preclinical studies involving cannabinoid administration in animal models of MS.
Analysis of existing clinical trial data for cannabinoid-based MS treatments.
Examination of emerging research on cannabinoid mechanisms of action related to neuroprotection.

Main Results:

Cannabinoids demonstrate a capacity to modulate experimental models of multiple sclerosis.
Clinical outcomes for cannabinoid use in MS symptom management have been variable.
Growing evidence suggests potential neuroprotective effects of cannabinoids.

Conclusions:

Cannabinoids may play a significant role in managing multiple sclerosis, both symptomatically and potentially disease-modifying.
Further well-designed clinical trials are necessary to establish the efficacy and safety of cannabinoids in MS.
The neuroprotective actions of cannabinoids warrant continued investigation for therapeutic development in MS.

Related Experiment Videos